Streetbeat News

Stock Prices

SCHW

Charles Schwab Corporation (NYSE:SCHW) reported Q1 earnings, with shares showing volatility in early trading. Analysts from JPMorgan, Piper Sandler, Goldman Sachs, and Keefe, Bruyette & Woods provided insights, adjusting their price targets and ratings based on the company's performance, including net interest income, cost management, and customer metrics. Key highlights include better-than-expected earnings per share, solid March metrics, stable core deposits, and strong retail engagement.

Portfolio Pulse from Priya Nigam

April 16, 2024 | 4:02 pm

AXP

Recent options trading activity indicates a bullish sentiment among big-money investors towards American Express (NYSE:AXP), with a notable split in sentiment (53% bullish, 46% bearish). The trading activity suggests a target price range of $150 to $240 for AXP over the next three months. The largest trades observed include both bullish and bearish positions, with significant amounts invested in calls and puts. American Express, a global financial institution, is currently trading at $217.13, with an earnings announcement expected in 3 days.

Portfolio Pulse from Benzinga Insights

April 16, 2024 | 4:02 pm

CASY

Analysts have provided diverse opinions on Casey's General Stores (NASDAQ:CASY), with recent ratings ranging from bullish to bearish. The average 12-month price target for CASY has been raised to $331.1. The company's financial performance shows a slight decline in revenue growth, but it maintains a strong net margin, ROE, and ROA, with a low debt-to-equity ratio. Casey's operates over 2,500 convenience stores in the Midwest, owning most of its real estate.

Portfolio Pulse from Benzinga Insights

April 16, 2024 | 4:01 pm

VRTX

Vertex Pharmaceuticals (NASDAQ:VRTX) has significantly outperformed the market with an average annual return of 19.19% over the past 10 years, turning a $1000 investment into $6,036.05 today. The company's market capitalization stands at $102.14 billion.

Portfolio Pulse from Benzinga Insights

April 16, 2024 | 4:00 pm

BAH

Booz Allen Hamilton (NYSE:BAH) has delivered an average annual return of 19.89% over the past 5 years, outperforming the market by 8.21%. A $100 investment in BAH 5 years ago would be worth $247.67 today. The company's market capitalization stands at $18.46 billion.

Portfolio Pulse from Benzinga Insights

April 16, 2024 | 4:00 pm

TGT

35 financial analysts have recently published ratings on Target (NYSE:TGT), showing a diverse range of perspectives from bullish to bearish. The latest assessments reveal an average 12-month price target of $181.86 for Target, indicating a 14.1% increase from the previous target. Analysts have adjusted their ratings and price targets based on changing market dynamics and Target's performance, with many raising their price targets. Target, the nation's sixth-largest retailer, has shown impressive revenue growth and financial performance, with a market capitalization indicating a reduced size compared to industry averages.

Portfolio Pulse from Benzinga Insights

April 16, 2024 | 4:00 pm

ADBE

GGME

GOOG

GOOGL

PNQI

Adobe Inc (NASDAQ:ADBE) is developing an AI model for video content creation to be integrated into Premiere Pro, competing with OpenAI's Sora and Alphabet Inc's (NASDAQ:GOOG) (NASDAQ:GOOGL) Google Imagen 2. The model introduces features for object addition/removal and generative extension, with plans to incorporate Content Credentials for identifying AI-generated content. Adobe is also integrating third-party tools from OpenAI, Runway, and Pika Labs, addressing Wall Street's concerns about AI-generated content tools. Adobe's stock is accessible via Invesco Next Gen Media And Gaming ETF (NYSE:GGME) and Invesco Nasdaq Internet ETF (NASDAQ:PNQI).

Portfolio Pulse from Anusuya Lahiri

April 16, 2024 | 3:51 pm

CLDI

Calidi Biotherapeutics Inc (NASDAQ:CLDI) shares plummeted by 59% to $0.25 after announcing a $6.1 million public offering, including various warrants. The proceeds are intended for working capital, general corporate purposes, and funding pre-clinical and clinical trials. The offering, with Ladenburg Thalmann & Co. Inc. as the sole placement agent, is expected to close by April 18.

Portfolio Pulse from Henry Khederian

April 16, 2024 | 3:48 pm

JAGX

Jaguar Health, Inc. (NASDAQ:JAGX) shares surged after announcing a 5-year exclusive in-license agreement with Venture Life Group PLC for Gelclair, an FDA-approved product for oral mucositis treatment. The deal marks Jaguar's entry into cancer supportive care. The stock experienced heavy trading volume, with over 240 million shares traded, significantly above its 100-day average. Despite a yearly decrease of 68.97%, JAGX has risen 172.33% over the past month. The stock's RSI of 70.7 suggests it is currently overbought.

Portfolio Pulse from Erica Kollmann

April 16, 2024 | 3:48 pm

PALI

Palisade Bio, Inc. (NASDAQ:PALI) shares surged after announcing successful analysis of PALI-2108, showing efficient conversion into its active form in stool samples from healthy volunteers and ulcerative colitis patients. The study's positive results have boosted investor confidence, with shares trading higher on heavy volume, significantly above the 100-day average.

Portfolio Pulse from Erica Kollmann

April 16, 2024 | 3:47 pm